Asset profile
SYH2053
RNA / oligonucleotide
Evidence outlook · registrational
Atherosclerotic Cardiovascular Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2027-12-31.
NCT07421232: The trial was randomized and participant-blinded, with placebo and inclisiran comparator groups, and enrolled 156 participants. Its primary endpoint was the clinically accepted LDL-C measure, but the outcome comparison cannot yet be assessed because results are not available.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
79 competitors in this universe: 18 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SYH2053: this drug | Phase 3 | RNA / oligonucleotide | PCSK9 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| AZD0780 | Phase 3 | Small molecule | PCSK9 | ||
| Ebronucimab | Phase 3 | Monoclonal antibody | PCSK9 | ||
| Enlicitide | Phase 3 | Peptide | PCSK9 | ||
| Lerodalcibep (Lerochol) | Phase 3 | Protein / enzyme therapeutic | PCSK9 | ||
| Ongericimab (Junshida) | Phase 3 | Monoclonal antibody | PCSK9 | ||
| QLC7401 | Phase 3 | RNA / oligonucleotide | PCSK9 | ||
| Recaticimab | Phase 3 | Monoclonal antibody | PCSK9 | ||
| Tafolecimab (Sintbilo) | Phase 3 | Monoclonal antibody | PCSK9 | ||
| AZD8233 | Phase 2 | RNA / oligonucleotide | PCSK9 | ||
| DNV001 | Phase 2 | Monoclonal antibody | PCSK9 | ||
| HRS-1301 | Phase 2 | Small molecule | PCSK9 | ||
| COR-1004 | Phase 1 | — | PCSK9 |
…and 64 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
12 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
2028 (1)
February 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.